William Baird’s Post

Drug Discovery Chemistry is in full swing!   Earlier today, our Associate Director for Target Biology, Alberto Moreno de la Gándara, shared updates on our platform, GlueSEEKER, in his talk, “Molecular Glue Discovery by High-throughput Neomorphic Remodelling of Effector Proteins”.   Phoremost is tackling undruggable diseases using our screening platforms, SITESEEKER and GlueSEEKER, which combine computational approaches with molecular biology to systematically identify targets in oncology and protein degradation.   Visit our website to learn more ➡️ https://lnkd.in/eURDPTtU   #DDCEurope #DrugDiscovery #ProteinDegraders

Three ERC Proof of Concept Grants are awarded to researchers in the #BISTCommunity 👏 🏅Dr. Francisco Pelayo García de Arquer from ICFO 🏅Dr. Pere Roca-Cusachs from the Institute for Bioengineering of Catalonia (IBEC) 🏅ICREA Prof. Ben Lehner from the Centre for Genomic Regulation (CRG) The researchers receive €150,000 grants to help bridge the gap between their existing research and the early phases of #commercialization. Their projects focus, respectively, on demonstrating a scalable process to produce #GreenHydrogen, a new approach to #CancerTherapy, and a scalable AI-powered peptide drug discovery platform. #Innovation #ERCPoC European Research Council (ERC) Learn more 👉 https://lnkd.in/gWKQACf6

Via Scientific, Inc. is proud to announce that we are exhibiting at #BioITExpo from Monday, April 15th, to Wednesday, April 17th, at the Omni Seaport in Boston, MA! Your mission is to “Cure the World,” and at Via Scientific, Inc., our mission is to help you by accelerating and expanding your therapeutics pipeline. Stop by Booth #212 to dive into the world of multi-omics and AI with our expert team. Discover how #ViaFoundry transforms your capacity to unravel critical insights in cellular biology, disease, and drug discovery. Let's accelerate your science together! #BioITExpo #PrecisionMedicine #bioinformatics #AI

Full video of the webinar is now available! Thanks to Hanadie, Alex, and Ben for a fascinating conversation about the many ways that AI can catalyze progress in longevity biotech.

📢[New Publication! - Engineered #cereblon optimized for #highthroughputscreening and molecular glue discovery] Most clinical degraders utilize an immunomodulatory imide drug (#IMiD)-based derivative that directs their target to the #E3ligase receptor cereblon (CRBN). However, identifying IMiD molecular glue substrates has remained underexplored. ➡️To address this, a recent collaborative study designed CRBN_ΔHBD, an engineered #cereblon construct designed for efficient, cost-effective expression in E. coli. Key findings in this study: 👉Researchers designed the "Enamine Focused IMiD Library" and demonstrated the construct’s applicability to high-throughput screening, successfully identifying binders with high potency, ligand efficiency, and specificity. 👉Adapted the CRBN construct for proof of principle glue screening approaches, enabling the determination of the IMiD cellular interactome. The authors believe that coupling the #CRBNconstruct with the IMiD binding landscape will provide a robust platform for exploring and identifying next-generation CRBN molecular glues. ➡️Team iBET - Instituto de Biologia Experimental e Tecnológica is proud to be part of this work recently published by Henry Bailey and Ivan Đikić, in collaboration with colleagues at Merck Healthcare, Enamine Germany, Radosław Nowak Lab, and the Langer Lab Max Planck Institute of Biophysics. Contratulations to all the authors! 👏 Full manuscript here 🔗https://lnkd.in/dgxXyU_m #IMiD #CRBN #DrugDiscovery #MolecularGlue #ProteinEngineering #TargetedProteinDegradation #iBET

#AmberGen is grateful for the opportunity to sponsor and exhibit at #IMSIS2024 in Münster, Germany. This is the premier annual event for the worldwide #MSI (Mass Spec Imaging) scientific community. Here I am visiting with Vaishnavi M.Natarajan, Ph.D and Marlien Kruse of Bielefeld University. Vai is a researcher who performs spatial metabolic profiling on a Bruker #timsTOF in her work. AmberGen’s Miralys(tm) MALDI HiPLEX-IHC is a perfect tool for scientists like Vai and Marlien who are already Mass Spec Imaging experts, and seek to take their research to the next level. #MSI is already the most multiomic imaging platform for #spatialbiology enabling imaging of small molecule drug distribution, lipidomics, metabolomics, untargeted glycomics, and peptidomics for biomarker discovery to be performed on tissue samples. AmberGen’s product enhances this by adding targeted proteomics, glycomics and transcriptomics to be added. What is remarkable is that all of this data can be collected using the same Maldi instrument, and amazingly on the same tissue sample. Tools like this will enable researchers like Vai to collect more information than ever before from their precious biological samples. Contact me at AmberGen to learn more. #IMSIS #multiomics #massspecimaging

Symposium on neutron scattering highlighted possibilities to advance drug discovery! The IPDD symposium on neutron scattering in May aimed to highlight ongoing research and possibilities with neutron scattering in drug design, discovery and formulation, and gathered around 25 researchers from Lund and Copenhagen as well as international speakers joining via zoom. Organisers Raminta Venskutonytė from the Medical Faculty at Lund University, and Zoë Fisher from ESS, reflect on the outcomes of the event. – The symposium provided good opportunities for participants to talk and network, with ample opportunities for in-depth conversations, says Raminta Venskutonytė, associate researcher at Medical Structural Biology, Lund University, and leader of the Structure-based Drug Design (SBDD) working group. – It was great to be able to highlight how neutrons fill an important gap in the drug discovery pipeline, and how they can be used as part of drug target validation, and drug discovery, shedding light on how ligands or drugs interact with their target. Finally, neutrons also have an application in optimizing drug formulation for efficient drug delivery, says Zoë Fisher. Zoë Fisher Vito Foderà Karin Lindkvist Raminta Venskutonytė https://lnkd.in/dtt-hf7F

🌟Thrilled to be chairing a dynamic panel discussion on The Future of Phenotypic Drug Discovery at #SLAS2025. Join our incredible panel of experts: Angela Oliveira Pisco, Director of Computational Biology insitro Christopher Moxham, CEO & Founder Transcripta Bio John Moffat, Distinguished Scientist Genentech Nasim Jamali, Director of Morphological Profiling Ardigen Not attending SLAS this year? No problem! We want to hear from you. Take our 3-minute survey on the future of phenotypic drug discovery—your insights will help shape the discussion. Results will be shared during the session and with the broader community after the conference on LinkedIn. 🔗 Take the survey here: https://lnkd.in/es2Snj7P #SLAS2025 #PhenotypicDrugDiscovery #LifeSciences #Innovation #drugdiscovery #PhenotypicScreening #TranslationalResearch #ComputationalBiology #PrecisionMedicine #BioPharma

Our recently published article is a preliminary study for our research project. This study investigated the cytotoxicity of agaro-oligosaccharides and neoagaro-oligosaccharides derived from red algae with an in vitro study using RAW 264.7 cell culture. This research can be considered a preliminary study to plan a more detailed laboratory analysis to provide more information about the potential of agaro-oligosaccharides and neoagaro-oligosaccharides. It is also a primary study to explore and develop the potential utilization of natural materials. Link to the article: https://lnkd.in/gph2ktfs Collaboration research with Pinki Anggrahini Puspitasari #cellculture #RAW264.7 #cytotoxicity #MTTassay #oligosaccharides #redalgae

2️⃣ [ 𝗧𝗛𝗘 𝗩𝗛𝗛 𝗧𝗢𝗢𝗟𝗕𝗢𝗫 ] 𝗨𝗻𝘃𝗲𝗶𝗹𝗶𝗻𝗴 𝗻𝗲𝘄 𝗳𝗿𝗼𝗻𝘁𝗶𝗲𝗿𝘀 𝗶𝗻 𝗧𝗮𝘂 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗡𝗮𝗻𝗼𝗯𝗼𝗱𝗶𝗲𝘀®🧬 We previously highlighted the groundbreaking role of our F8-2 nanobody in degrading aggregated Tau, as featured in Science (2024). Now, we’re excited to highlight another achievement from our 𝗩𝗛𝗛 𝗧𝗼𝗼𝗹𝗯𝗼𝘅. 🔍 𝗠𝗲𝗲𝘁 𝗘𝟰-𝟭/𝗭𝟳𝟬 : This nanobody, derived from the same selection family as F8-2, represents another breakthrough ! Through an innovative intrabodization process, E4-1, also known as Z70, was optimized to specifically bind to the Tau aggregation epitope PHF6. It effectively inhibits Tau aggregation 𝑖𝑛 𝑣𝑖𝑡𝑟𝑜, 𝑖𝑛 𝑐𝑒𝑙𝑙𝑢𝑙𝑜, and 𝑖𝑛 𝑣𝑖𝑣𝑜 after delivery via a viral system.     This significant work, published by Isabelle Landrieu and Luc Buee’s team in Molecular Therapy, highlights another facet of our VHH technology’s potential.      Curious about how our nanobodies can drive your research forward? ➡️ https://lnkd.in/eKYNXnDv  #Innovation #Biotechnology #Nanobodies #Tau #ScientificResearch #HybrigenicsServices #VHH #TauAggregation